CSIMarket Company Name, Ticker, Industry, else..
 

Synlogic Inc   (SYBX)

Synlogic Inc 's

Competitiveness



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

 

SYBX Sales vs. its Competitors Q2 2026


Comparing the current results to its competitors, Synlogic Inc reported Revenue decrease in the 2 quarter 2026 year on year by 0 %, despite the revenue increase by the most of its competitors of 3.61 %, recorded in the same quarter.

• List of SYBX Competitors





Revenue Growth Comparisons




Net Income Comparison

Synlogic Inc , faster than the decline experienced by the competitors recorded a net loss, as well as most of its competitors.

<<  SYBX Stock Performance Comparisons





*Market share is calculated based on total revenue.

  News about Synlogic Inc Contracts

Synlogic Bagged Contract from Air Force, Reflecting the Company's Synthetic Biology Prowess despite Revenue Dips

December 27, 2023
 Synthetic biology leader, Synlogic Inc., has recently announced a significant contract with the Air Force Research Laboratory. This recent alignment underscores the company s prowess in process development and manufacturing of therapeutics hinged on synthetic biology. However, this positive development also enlisted alongside an unfortunate decline in company revenues in the third quarter of 2023. The contract from the Air Force Research Lab fortifies Synlogic s standing in its operational vertical. Over the years, Synlogic has been a game-changer in crafting therapeutics based on synthetic biology. By partnering up with such a major entity, Synlogic further cements its authority as a leader in this innovati...





Publicly Traded Peers of Synlogic Inc




Zyversa Therapeutics Inc
Share Performance



-43.43%
This Quarter
Zyversa Therapeutics Inc
Profile

Zyversa Therapeutics Inc's business model revolves around developing innovative therapies and treatments for various medical conditions.

More about Zyversa Therapeutics Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 0.801 mill. $ - mill. $ -24.489 mill.


Medicure Inc
Share Performance



0.00%
One Year
Medicure Inc
Profile

Medicure Inc operates as a pharmaceutical company with a business model that focuses on the research, development, and commercialization of innovative cardiovascular and other specialty pharmaceuticals. They aim to address unmet medical needs, improve patient outcomes, and deliver value to healthcare providers and consumers.

More about Medicure Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ - mill. $ 25.925 mill. $ -5.920 mill.


Medicinova Inc
Share Performance



+47.09%
One Year
Medicinova Inc
Profile

Medicinova Inc operates under a biopharmaceutical business model, primarily focused on the development and commercialization of innovative therapeutics. They strive to identify promising drug candidates with the potential to address unmet medical needs and advance them through clinical trials. By leveraging their research capabilities, strategic partnerships, and licensing opportunities, Medicinova Inc aims to bring these novel treatments to market and improve patient outcomes.

More about Medicinova Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 89.051 mill. $ 0.920 mill. $ -10.753 mill.


Mannkind Corporation
Share Performance



-32.32%
This Year
Mannkind Corporation
Profile

MannKind Corporation is a biopharmaceutical company that focuses on the development and commercialization of inhaled therapeutic solutions for patients with diseases such as diabetes and pulmonary arterial hypertension. The company's business model revolves around conducting research and development to create innovative inhalation therapies and gaining regulatory approvals for these treatments. They then market and distribute their products, either directly or through partnerships, to healthcare providers and patients worldwide.

More about Mannkind Corporation's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 1,171.834 mill. $ 393.630 mill. $ -43.614 mill.


Moonlake Immunotherapeutics
Share Performance



+7.78%
This Year
Moonlake Immunotherapeutics
Profile

Moonlake Immunotherapeutics's business model revolves around the development and commercialization of innovative immunotherapies for the treatment of diseases.

More about Moonlake Immunotherapeutics's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 952.029 mill. $ - mill. $ -265.223 mill.

38 more competitors available

Sign in to see all competitors

Sign In Create Free Account

Sources: Synlogic Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Synlogic Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.